# Inhaled corticosteroids for abnormal pulmonary function in children with a history of Chronic Lung Disease of Infancy: study protocol [ISRCTN55153521]

## TL;DR

This study aims to determine if inhaled corticosteroids improve lung function and quality of life in children with a history of chronic lung disease of infancy.

## Contribution

The study introduces a randomized, placebo-controlled trial to evaluate the clinical effectiveness of inhaled corticosteroids in children with chronic lung disease of infancy.

## Key findings

- The trial will assess if Beclomethasone Dipropionate improves respiratory resistance in children with CLD.
- The study will evaluate the impact of inhaled steroids on quality of life in children aged 3 to 9 with a history of CLD.

## Abstract

There is considerable evidence from the literature that children with chronic lung disease of infancy (CLD) have abnormal pulmonary function in childhood and this could have an impact on their life quality and overall health. There are similarities between CLD and asthma, and corticosteroids are the mainstay treatment for asthma. Many physicians use inhaled corticosteroids in children with CLD with no evidence. Therefore we wish to conduct a randomized double-blinded placebo controlled trial to test for the role of inhaled corticosteroids in children aged from3 to 9 years with a history of CLD. Our primary hypothesis will be that inhaled corticosteroids are beneficial in children with CLD.

Our primary hypothesis is that using inhaled steroids; Beclomethasone Dipropionate (QVAR) 100 mcg 2 puffs 2 times a day for 6 weeks will improve the respiratory system resistance and the quality of life in children with CLD.

We propose that Beclomethasone Dipropionate (QVAR) will affect the pulmonary function after 6 weeks of treatment. In summary we think that our study will highlight knowledge on whether the use of inhaled steroids is clinically effective for CLD.